MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD – Get Free Report) was down 6.8% on Friday . The stock traded as low as $0.13 and last traded at $0.15. Approximately 6,687,900 shares were traded during trading, an increase of 4,886% from the average daily volume of 134,123 shares. The stock had previously closed at $0.16.
MyMD Pharmaceuticals Stock Performance
The firm’s 50-day simple moving average is $0.20 and its two-hundred day simple moving average is $0.62.
MyMD Pharmaceuticals Company Profile
MyMD Pharmaceuticals, Inc, a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression.
Read More
- Five stocks we like better than MyMD Pharmaceuticals
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- RH Stock Rockets on Surprise Profit and Tariff Shift
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Synopsys Stock Falls on China Ban, But Long-Term Outlook Holds
- What is Forex and How Does it Work?
- Alphabet Enters a Bull Market: Is It Time to Buy?
Receive News & Ratings for MyMD Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyMD Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
